Discounted Cash Flow (DCF) Analysis Levered
Cellect Biotechnology Ltd. Warrants... (APOPW)
$0.0876
-0.00 (-%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P |
| Revenue |
|---|
| Revenue (%) |
| Operating Cash Flow |
| Operating Cash Flow (%) |
| Capital Expenditure |
| Capital Expenditure (%) |
| Free Cash Flow |
Weighted Average Cost Of Capital
| Share price | $ 0.0,876 |
|---|---|
| Beta | 2.267 |
| Diluted Shares Outstanding | - |
| Cost of Debt | |
| Tax Rate | - |
| After-tax Cost of Debt | -% |
| Risk-Free Rate | |
| Market Risk Premium | |
| Cost of Equity | 14.108 |
| Total Debt | - |
| Total Equity | - |
| Total Capital | - |
| Debt Weighting | - |
| Equity Weighting | - |
| Wacc |
Build Up Free Cash Flow
Year A/P |
| Revenue |
|---|
| Operating Cash Flow |
| Capital Expenditure |
| Free Cash Flow |
| WACC |
| PV LFCF |
| SUM PV LFCF |
Terminal Value
| Growth in perpetuity method: | |
|---|---|
| Long-term growth rate | |
| WACC (%) | - |
| Free cash flow (t + 1) | - |
| Terminal Value | - |
| Present Value of Terminal Value | - |
Intrinsic Value
| Enterprise Value | - |
|---|---|
| Net Debt | - |
| Equity Value | - |
| Shares Outstanding | - |
| Equity Value Per Share | - |